| 15.31 0.07 (0.46%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.09  |
1-year : | 20.14 |
| Resists | First : | 16.35 |
Second : | 17.25 |
| Pivot price | 16.05 |
|||
| Supports | First : | 14.89 |
Second : | 12.39 |
| MAs | MA(5) : | 15.51 |
MA(20) : | 16.08 |
| MA(100) : | 16.86  |
MA(250) : | 17.74 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 10.9 |
| RSI | RSI(14): 38.9 |
|||
| 52-week | High : | 23.8 | Low : | 11.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VRNA ] has closed above bottom band by 12.7%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.47 - 15.56 | 15.56 - 15.64 |
| Low: | 14.67 - 14.79 | 14.79 - 14.89 |
| Close: | 15.15 - 15.31 | 15.31 - 15.46 |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Thu, 25 Apr 2024
Verona Pharma plc (NASDAQ:VRNA) Shares Acquired by Jennison Associates LLC - MarketBeat
Thu, 25 Apr 2024
(VRNA) Investment Analysis and Advice - Stock Traders Daily
Thu, 25 Apr 2024
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewswire
Mon, 22 Apr 2024
Biopharma's New Drug for COPD Likely to be Approved Research Report - Streetwise Reports
Wed, 20 Mar 2024
Verona Pharma plc's (NASDAQ:VRNA) Profit Outlook - Simply Wall St
Thu, 29 Feb 2024
Verona Pharma plc (VRNA) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 77 (M) |
| Shares Float | 440 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 85.6 (%) |
| Shares Short | 6,560 (K) |
| Shares Short P.Month | 6,340 (K) |
| EPS | -0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -22.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -21.27 |
| PEG Ratio | 0 |
| Price to Book value | 4.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -23.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|